Compare Gilead Sciences, Inc. (GILD) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Paychex, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.59 (market cap $163.51B), while Paychex, Inc. trades at $114.79 (market cap $39.12B). The key difference: Gilead Sciences, Inc. is far larger — about 4.2× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.33%). Which is the better fit depends on your goals.
| GILD | PAYX | |
|---|---|---|
Market Cap | $163.51B | $39.12B |
Sector | Health | Industrials |
52-Week High | $155.80 | $147.99 |
52-Week Low | $108.22 | $85.57 |
Enterprise Value | $178.05B | $42.60B |
Dividend Yield | 2.49% | 4.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Paychex (PAYX) trades at $114.45, up 4.5% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 exceeding expectations, and maintains impressive profitability with 27.03% net income margin and 44.77% ROE. Recent dividend declaration of $1.19 per share and positive business developments including AI expansion support growth outlook.
While valuation metrics appear elevated with P/E of 22.49 and P/S of 6.08, Paychex's strong cash flow generation and market leadership position provide investment appeal. Key risks include competitive pressures and macroeconomic sensitivity to small business hiring trends. Analyst consensus remains cautious with only 16.67% buy ratings, though technical indicators suggest near-term bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
